高级检索
中华内科杂志
期刊首页
过刊列表
高级检索
稿件发表
• 标准与讨论 •
ENGLISH ABSTRACT
成人T细胞白血病/淋巴瘤诊断与治疗中国专家共识（2024年版）
中国医师协会血液科医师分会
中国医疗保健国际交流促进会血液学分会
作者及单位信息
·
DOI： 10.3760/cma.j.cn112138-20240918-00586
Chinese expert consensus on the diagnosis and treatment of adult T-cell leukemia/lymphoma (2024)
Hematology Physicians Committee of Chinese Medical Doctor Association
China International Exchange and Promotive Association for Medical and Healthcare, Society of Hematology
Wang Shaoyuan
Huang Xiaojun
Wu Depei
Authors Info & Affiliations
Hematology Physicians Committee of Chinese Medical Doctor Association
China International Exchange and Promotive Association for Medical and Healthcare, Society of Hematology
Wang Shaoyuan
Fujian Medical University Union Hospital,Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fuzhou 350001, China
Huang Xiaojun
Peking University People′s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Beijing 100044, China
Wu Depei
the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China
·
DOI： 10.3760/cma.j.cn112138-20240918-00586
980
424
0
0
21
2
PDF下载
APP内阅读
摘要

成人T细胞白血病/淋巴瘤（ATL）是一种少见且独特的T淋巴细胞增殖性肿瘤，发病与Ⅰ型人类嗜T淋巴细胞病毒（HTLV-1）感染密切相关。ATL临床特征异质性强，耐药常见，机会性感染频繁，预后差，是一种极具挑战性的疾病。由于ATL发病例数较少，国内对该疾病的认识尚未统一，诊疗尚不规范。为加强我国临床医师对ATL的认知，中国血液学专家结合国内外的最新研究进展，讨论并制订了《成人T细胞白血病/淋巴瘤诊断与治疗中国专家共识（2024年版）》。本共识提出中国ATL最新的诊断标准与分型标准，并简述了HTLV-1在中国沿海地区的感染情况，国内ATL的流行趋势、发病机制、临床表现、治疗策略等方面的最新证据和建议，旨在规范ATL的临床诊治，改善ATL患者的总体生存。

成人T细胞白血病/淋巴瘤;人类嗜T淋巴细胞病毒1型;诊断，分型;鉴别诊断;治疗
ABSTRACT

Adult T-cell leukemia/lymphoma (ATL), a rare and unique proliferative tumor of T lymphocytes, is associated with human T-cell leukemia virus type 1 (HTLV-1) infection. Due to its diverse clinical features, multidrug resistance of malignant cells, frequent opportunistic infection, and poor prognosis, ATL remains a clinical challenge. A unified understanding of ATL is currently lacking, and its diagnosis and treatment are not standardized in China due to the small number of cases. Therefore, to strengthen our understanding of ATL, hematology experts have formulated the "Chinese expert consensus on the diagnosis and treatment of adult T-cell leukemia/lymphoma (2024)" based on the latest research progress at home and abroad. This consensus proposes the latest diagnostic and subtype criteria for ATL in China. Furthermore, it briefly describes the infection situation of HTLV-1 in coastal areas of China, the epidemic trends in China, and the latest evidence and recommendations regarding the pathogenesis, clinical manifestations, and treatment strategies, with the aim to standardize the clinical diagnosis and treatment of ATL and ultimately improve the overall survival of patients with ATL.

Adult T-cell leukemia/lymphoma;Human T-lymphotropic virus 1;Diagnosis, subtype;Differential diagnosis;Therapy
Wang Shaoyuan, Fujian Medical University Union Hospital,Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fuzhou 350001, China, Email: nc.defudabe.umjfgnawnauyoahs
Huang Xiaojun, Peking University People′s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Beijing 100044, China, Email: nc.defudabe.umjbnujoaixgnauh
Wu Depei, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China, Email: nc.defudabe.adusiepeduw
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

中国医师协会血液科医师分会,中国医疗保健国际交流促进会血液学分会. 成人T细胞白血病/淋巴瘤诊断与治疗中国专家共识（2024年版）[J]. 中华内科杂志,2024,63(12)：1196-1204.

DOI:10.3760/cma.j.cn112138-20240918-00586

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

成人T细胞白血病/淋巴瘤（adult T cell leukemia/lymphoma，ATL）是一种少见且独特的T淋巴细胞增殖性肿瘤，发病与Ⅰ型人类嗜T淋巴细胞病毒（human T-cell lymphotropic virus type 1，HTLV-1）感染密切相关 ［ 1 ］ 。全球HTLV-1感染总人数约在500万~1 000万 ［ 2 ］ ，2%~5%HTLV-1感染者在长时间的潜伏期后发展为ATL ［ 3 ］ 。该病与HTLV-1分布特点类似，呈区域性流行，高发于日本北部和南部、加勒比地区、非洲、中东部分地区、南部和中美洲 ［ 4 ］ 。ATL临床特征异质性强、耐药常见、机会性感染频繁、预后差，因此，是一种极具挑战性的疾病 ［ 5 ］ 。
国内不同地区HTLV-1感染率不尽相同，回顾性研究报道近10年中国HTLV-1阳性感染者集中来源于福建、广东和浙江。福建主要集中在宁德、莆田等沿海地区，HTLV-1感染率高于北美和欧洲等发达地区，且ATL发病率显著高于内地其他地区 ［ 6 , 7 ］ 。由于ATL发病例数较少，国内对该疾病的认识尚未统一，诊疗尚不规范。为加强我国临床医师对ATL的认知，提高诊断、鉴别诊断及治疗水平，中国血液学专家结合自己的临床经验以及国内外最新的研究进展，经过反复讨论与修改，制订了本共识。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Cook LB , Phillips AA . How I treat adult T-cell leukemia/lymphoma[J]. Blood, 2021,137(4):459-470. DOI: 10.1182/blood.2019004045 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Gallo RC , Willems L , Hasegawa H ,et al. Screening transplant donors for HTLV-1 and-2[J]. Blood, 2016,128(26):3029-3031. DOI: 10.1182/blood-2016-09-739433 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Zuo X , Zhou R , Yang S ,et al. HTLV-1 persistent infection and ATLL oncogenesis[J]. J Med Virol, 20 23 ,95(1):e28424. DOI: 10.1002/jmv.28424 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Shah UA , Shah N , Qiao B ,et al. Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States[J]. Cancer, 2020,126(3):567-574. DOI: 10.1002/cncr.32556 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Cook LB , Fuji S , Hermine O ,et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report[J]. J Clin Oncol, 2019,37(8):677-687. DOI: 10.1200/JCO.18.00501 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
谢桂芸,陈锦艳,黎世杰,等. 近10年中国大陆献血者HTLV感染情况的meta分析[J]. 中国输血杂志, 2021,34(12):1332-1338. DOI: 10.13303/j.cjbt.issn.1004-549x.2021.12.014 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Luo L , Chen Y , Wu Z ,et al. Clinical characteristics, genetic alterations, and prognosis of adult T-cell leukemia/lymphoma: an 11-year multicenter retrospective study in China[J]. Am J Cancer Res, 2024,14(4):1649-1661. DOI: 10.62347/RARP1733 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Uchiyama T , Yodoi J , Sagawa K ,et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases[J]. Blood, 1977,50(3):481-492.
返回引文位置Google Scholar
百度学术
万方数据
[9]
Durer C , Babiker HM . Adult T-cell leukemia[M]. Treasure Island:StatPearls Publishing, 2024.
返回引文位置
[10]
Alaggio R , Amador C , Anagnostopoulos I ,et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms[J]. Leukemia, 2022,36(7):1720-1748. DOI: 10.1038/s41375-022-01620-2 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Mehta-Shah N , Ratner L , Horwitz SM . Adult T-cell leukemia/lymphoma[J]. J Oncol Pract, 2017,13(8):487-492. DOI: 10.1200/JOP.2017.021907 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Ishitsuka K . Diagnosis and management of adult T-cell leukemia/lymphoma[J]. Semin Hematol, 2021,58(2):114-122. DOI: 10.1053/j.seminhematol.2021.02.005 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Sawada Y , Hino R , Hama K ,et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma[J]. Blood, 2011,117(15):3961-3967. DOI: 10.1182/blood-2010-11-316794 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Shimoyama M . Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)[J]. Br J Haematol, 1991,79(3):428-437. DOI: 10.1111/j.1365-2141.1991.tb08051.x .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Kamihira S , Atogami S , Sohda H ,et al. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia[J]. Cancer, 1994,73(11):2753-2758. DOI: 10.1002/1097-0142(19940601)73∶11<2753::aid-cncr2820731117>3.0.co;2-x .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Tsukasaki K , Hermine O , Bazarbachi A ,et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting[J]. J Clin Oncol, 2009,27(3):453-459. DOI: 10.1200/JCO.2008.18.2428 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Takasaki Y , Iwanaga M , Tsukasaki K ,et al. Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL)[J]. Leuk Res, 2007,31(6):751-757. DOI: 10.1016/j.leukres.2006.11.013 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Yoshie O , Fujisawa R , Nakayama T ,et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells[J]. Blood, 2002,99(5):1505-1511. DOI: 10.1182/blood.v99.5.1505 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Roncador G , Garcia JF , Garcia JF ,et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma[J]. Leukemia, 2005,19(12):2247-2253. DOI: 10.1038/sj.leu.2403965 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Nicot C . Current views in HTLV-I-associated adult T-cell leukemia/ lymphoma [J]. Am J Hematol, 2005,78(3):232-239. DOI: 10.1002/ajh.20307 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Kamada N , Sakurai M , Miyamoto K ,et al. Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report[J]. Cancer Res, 1992,52(6):1481-1493.
返回引文位置Google Scholar
百度学术
万方数据
[22]
Rowan AG , Dillon R , Witkover A ,et al. Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis[J]. Blood, 2020,135(23):2023-2032. DOI: 10.1182/blood.2019002665 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
吴正军,郑晓云,杨小珠,等. 经HTLV-1前病毒基因检测确诊的12例成人T细胞白血病/淋巴瘤临床特征及预后分析[J]. 中华血液学杂志, 2016,37(12):1027-1032. DOI: 10.3760/cma.j.issn.0253-2727.2016.12.003 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Okuma K , Kuramitsu M , Niwa T ,et al. Establishment of a novel diagnostic test algorithm for human T-cell leukemia virus type 1 infection with line immunoassay replacement of western blotting: a collaborative study for performance evaluation of diagnostic assays in Japan[J]. Retrovirology, 2020,17(1):26. DOI: 10.1186/s12977-020-00534-0 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Tsukasaki K , Fukushima T . JSH practical guidelines for hematological malignancies, 2018: Ⅱ. Lymphoma-8. Adult T-cell leukemia-lymphoma[J]. Int J Hematol, 2019,109(3):249-259. DOI: 10.1007/s12185-018-02588-5 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Takasaki Y , Iwanaga M , Imaizumi Y ,et al. Long-term study of indolent adult T-cell leukemia-lymphoma[J]. Blood, 2010,115(22):4337-4343. DOI: 10.1182/blood-2009-09-242347 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Katsuya H , Shimokawa M , Ishitsuka K ,et al. Prognostic index for chronic-and smoldering-type adult T-cell leukemia-lymphoma[J]. Blood, 201 7 ,130(1):39-47. DOI: 10.1182/blood-2017-01-757542 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Fuji S , Yamaguchi T , Inoue Y ,et al. Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation[J]. Haematologica, 2017,102(7):1258-1265. DOI: 10.3324/haematol.2017.164996 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Ohtsuka M , Hamada T , Miyagaki T ,et al. Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020[J]. J Dermatol, 2021,48(2):e49-e71. DOI: 10.1111/1346-8138.15707 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
Tsukasaki K , Utsunomiya A , Fukuda H ,et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801[J]. J Clin Oncol, 2007,25(34):5458-5464. DOI: 10.1200/JCO.2007.11.9958 .
返回引文位置Google Scholar
百度学术
万方数据
[31]
Teshima T , Akashi K , Shibuya T ,et al. Central nervous system involvement in adult T-cell leukemia/lymphoma[J]. Cancer, 1990,65(2):327-332. DOI: 10.1002/1097-0142(19900115)65∶2<327::aid-cncr2820650224>3.0.co;2-w .
返回引文位置Google Scholar
百度学术
万方数据
[32]
Gill PS , Harrington W Jr, Kaplan MH ,et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine[J]. N Engl J Med, 1995,332(26):1744-1748. DOI: 10.1056/NEJM199506293322603 .
返回引文位置Google Scholar
百度学术
万方数据
[33]
Abdelmoumen K , Alsibai KD , Rabier S ,et al. Adult T-cell leukemia and lymphoma in French Guiana: a retrospective analysis with real-life data from 2009 to 2019[J]. Lancet Reg Health Am, 2023,21:100492. DOI: 10.1016/j.lana.2023.100492 .
返回引文位置Google Scholar
百度学术
万方数据
[34]
Hermine O , Allard I , Lévy V ,et al. A prospective phase Ⅱ clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma[J]. Hematol J, 2002,3(6):276-282. DOI: 10.1038/sj.thj.6200195 .
返回引文位置Google Scholar
百度学术
万方数据
[35]
Datta A , Bellon M , Sinha-Datta U ,et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence[J]. Blood, 2006,108(3):1021-1029. DOI: 10.1182/blood-2006-01-0067 .
返回引文位置Google Scholar
百度学术
万方数据
[36]
Ishida T , Jo T , Takemoto S ,et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase Ⅱ study[J]. Br J Haematol, 2015,169(5):672-682. DOI: 10.1111/bjh.13338 .
返回引文位置Google Scholar
百度学术
万方数据
[37]
Horwitz S , O′Connor OA , Pro B ,et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial[J]. Lancet, 2019,393(10168):229-240. DOI: 10.1016/S0140-6736(18)32984-2 .
返回引文位置Google Scholar
百度学术
万方数据
[38]
Utsunomiya A . Progress in allogeneic hematopoietic cell transplantation in adult T-cell leukemia-lymphoma [J]. Front Microbiol, 2019,10:2235. DOI: 10.3389/fmicb.2019.02235 .
返回引文位置Google Scholar
百度学术
万方数据
[39]
Inoue Y , Fuji S , Tanosaki R ,et al. Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma[J]. Bone Marrow Transplant, 2018,53(9):1105-1115. DOI: 10.1038/s41409-018-0139-z .
返回引文位置Google Scholar
百度学术
万方数据
[40]
Yoshimitsu M , Utsunomiya A , Fuji S ,et al. A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma[J]. Bone Marrow Transplant, 2019,54(8):1266-1274. DOI: 10.1038/s41409-018-0400-5 .
返回引文位置Google Scholar
百度学术
万方数据
[41]
Ito A , Nakano N , Tanaka T ,et al. Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study[J]. Blood Adv, 2021,5(20):4156-4166. DOI: 10.1182/bloodadvances.2021004932 .
返回引文位置Google Scholar
百度学术
万方数据
[42]
Focosi D , Petrini M . More on donor-derived T-cell leukemia after bone marrow transplantation[J]. N Engl J Med, 2006,355(2):212-213; author reply 213. DOI: 10.1056/NEJMc061054 .
返回引文位置Google Scholar
百度学术
万方数据
[43]
Okamura J , Utsunomiya A , Tanosaki R ,et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma[J]. Blood, 2005,105(10):4143-4145. DOI: 10.1182/blood-2004-11-4193 .
返回引文位置Google Scholar
百度学术
万方数据
[44]
Inoue Y , Nakano N , Fuji S ,et al. Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma[J]. Bone Marrow Transplant, 2021,56(12):2964-2974. DOI: 10.1038/s41409-021-01445-0 .
返回引文位置Google Scholar
百度学术
万方数据
[45]
Fuji S , Inoue Y , Utsunomiya A ,et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality[J]. J Clin Oncol, 2016,34(28):3426-3433. DOI: 10.1200/JCO.2016.67.8250 .
返回引文位置Google Scholar
百度学术
万方数据
[46]
Sharma K , Janik JE , O′Mahony D ,et al. Phase Ⅱ study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma[J]. Clin Cancer Res, 2017,23(1):35-42. DOI: 10.1158/1078-0432.CCR-16-1022 .
返回引文位置Google Scholar
百度学术
万方数据
[47]
Ceesay MM , Matutes E , Taylor GP ,et al. Phase Ⅱ study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL)[J]. Leuk Res, 2012,36(7):857-861. DOI: 10.1016/j.leukres.2011.12.004 .
返回引文位置Google Scholar
百度学术
万方数据
[48]
Ishida T , Joh T , Uike N ,et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase Ⅱ study[J]. J Clin Oncol, 2012,30(8):837-842. DOI: 10.1200/JCO.2011.37.3472 .
返回引文位置Google Scholar
百度学术
万方数据
[49]
Ishida T , Fujiwara H , Nosaka K ,et al. Multicenter phase Ⅱ study of lenalidomide in relapsed or recurrent adult T-Cell leukemia/lymphoma: ATLL-002[J]. J Clin Oncol, 2016,34(34):4086-4093. DOI: 10.1200/JCO.2016.67.7732 .
返回引文位置Google Scholar
百度学术
万方数据
[50]
Utsunomiya A , Izutsu K , Jo T ,et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results[J]. Cancer Sci, 2022,113(8):2778-2787. DOI: 10.1111/cas.15431 .
返回引文位置Google Scholar
百度学术
万方数据
[51]
Stuver R , Horwitz SM , Epstein-Peterson ZD . Treatment of adult T-cell leukemia/lymphoma: established paradigms and emerging directions[J]. Curr Treat Options Oncol, 2023,24(8):948-964. DOI: 10.1007/s11864-023-01111-1 .
返回引文位置Google Scholar
百度学术
万方数据
[52]
O′Connor OA , Horwitz S , Hamlin P ,et al. Phase Ⅱ-I-Ⅱ study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies[J]. J Clin Oncol, 2009,27(26):4357-4364. DOI: 10.1200/JCO.2008.20.8470 .
返回引文位置Google Scholar
百度学术
万方数据
[53]
Maeda T , Babazono A , Nishi T ,et al. The impact of opportunistic infections on clinical outcome and healthcare resource uses for adult T cell leukaemia[J]. PLoS One, 2015,10(8):e0135042. DOI: 10.1371/journal.pone.0135042 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
王少元，福建医科大学附属协和医院 福建省血液病研究所 福建省血液病重点实验室，福州 350001，Email： nc.defudabe.umjfgnawnauyoahs
B
黄晓军，北京大学人民医院 北京大学血液病研究所 国家血液系统疾病临床医学研究中心，北京 100044，Email： nc.defudabe.umjbnujoaixgnauh
C
吴德沛，苏州大学附属第一医院 江苏省血液研究所 国家血液系统疾病临床医学研究中心，苏州 215006，Email： nc.defudabe.adusiepeduw
D
中国医师协会血液科医师分会, 中国医疗保健国际交流促进会血液学分会. 成人T细胞白血病/淋巴瘤诊断与治疗中国专家共识（2024年版）[J]. 中华内科杂志, 2024, 63(12): 1196-1204. DOI: 10.3760/cma.j.cn112138-20240918-00586.
E
所有作者声明无利益冲突
F
国家自然科学基金 (82070157，82000210)
国家重点研发计划 (2022YFC2502700)
国家临床重点专科建设项目 (闽卫医政2021-76号)
福建省恶性血液病临床医学研究中心项目 (2020Y2006)
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
老年弥漫大B细胞淋巴瘤诊断与治疗中国专家共识（2024年版）
中华医学会血液学分会淋巴细胞疾病学组 等
中华血液学杂志 2024,45(04)
中国成人急性淋巴细胞白血病诊断与治疗指南（2024年版）
中国抗癌协会血液肿瘤专业委员会 等
中华血液学杂志 2024,45(05)
中国噬血细胞综合征诊断与治疗指南（2022年版）
中国医师协会血液科医师分会 等
中华医学杂志 2022,102(20)
中国成人急性淋巴细胞白血病诊断与治疗指南（2021年版）
中国抗癌协会血液肿瘤专业委员会 等
中华血液学杂志 2021,42(09)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大